36 C
Vientiane
Sunday, April 27, 2025
spot_img
Home Blog Page 314

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ — Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently developed by Gan & Lee, in the US participants with overweight or obesity. Notably, bofanglutide is the first GLP-1 receptor mono-agonist to undergo a head-to-head comparison with tirzepatide for evaluating the efficacy in body weight management globally.

This Phase 2 clinical trial (ClinicalTrials.gov registration number: NCT06737042) was designed to evaluate the efficacy and safety of bofanglutide injection in US adults with overweight or obesity. The study plans to enroll 285 subjects, who will be randomized to receive either 24 mg, 36 mg, or 48 mg of bofanglutide bi-weekly, 15 mg of tirzepatide once-weekly, or placebo. The primary endpoint is the percentage change in body weight from baseline at the end of the treatment.

Previously, a Phase 1 study (NCT06548997) of bofanglutide injection demonstrated good safety and tolerability in US subjects, along with promising glucose-lowering and weight-loss potential[1]. The initiation of head-to-head clinical study for bofanglutide versus tirzepatide, marking a new phase in Gan & Lee’s GLP-1 innovation. This milestone underscores the company’s ambition to challenge the leading GLP-1 therapy in the global market for weight management, aiming to provide a better treatment option for patients with overweight or obesity worldwide.

Reference:

[1].Liu Y, Chen W, He X, He A, Zhao L, Xie T, Li Y, Zhao J, Hunt A, Shi A, Gan ZR. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16285. Epub ahead of print. PMID: 40028667.

About Bofanglutide (GZR18)

Bofanglutide (R&D Code: GZR18) injection, developed by Gan & Lee Pharmaceuticals, is a bi-weekly GLP-1 receptor agonist (RA) indicated for glycemic control in adults with type 2 diabetes and body weight management in overweight/obese individuals. As the potential first bi-weekly GLP-1 RA in the world, early clinical trials have demonstrated its efficacy in weight reduction comparable to or superior to marketed counterparts, with a safety and tolerability profile consistent with the established class of GLP-1 RAs, and significant reductions in both blood glucose levels and body weight.

Forward-looking statements

Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin®™), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (25R) (Prandilin®™25), aspart 30 injection (Rapilin30), and one human insulin injection – mixed protamine human insulin injection (30R) (Similin30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine)®.

In China’s 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets®.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.

Movement Network Foundation Announces Public Mainnet Beta Now Live with $250M+ TVL

Innovative day-one liquidity fuels the latest Move blockchain network launch

GRAND CAYMAN, Cayman Islands, March 10, 2025 /PRNewswire/ — The Movement Network Foundation, the organization dedicated to advancing MoveVM technology, today announced the successful launch of Movement Public Mainnet Beta, with an impressive $250M in at-launch Total Value Locked (TVL) from the Cornucopia program. This milestone enables permissionless smart contract deployment and user onboarding for the first time and allows everyone to freely build on and use Movement, the only Move-based chain that settles to Ethereum.

Cornucopia Deepens Liquidity

“Securing over $233 million in TVL through our Cornucopia program is a clear validation of the market’s confidence in Movement,” said Cooper Scanlon, Co-Founder of Movement Labs. “This level of day-one liquidity is exceptionally rare for a new network and gives us, our builders, and our community a significant advantage. It allows us to skip the months-long bootstrapping phase and immediately provide the foundation needed for meaningful DeFi adoption and utility.”

Cornucopia provides Movement Network with substantial day-one liquidity across BTC, ETH, MOVE, and stablecoin assets, addressing one of the primary challenges new networks face: the “cold start” problem. Developed with industry leaders including Concrete, Veda Labs, Echelon and Canopy, this robust financial foundation enables Movement to support sophisticated DeFi applications from day one.

Public Mainnet Beta Launch: Features

Movement Network is a secure and scalable network of Move-based chains secured by Ethereum, creating safer execution environments through the Move programming language originally developed by Meta to power safer, better digital economies. Movement is the Network’s first chain.

Public Mainnet Beta key features:

  • Permissionless smart contract deployment
  • Full user onboarding and engagement
  • Attestations of block states will be committed to Ethereum as part of the Movement’s Fast Finality Settlement.
  • Canonical Movement bridge via LayerZero

“With Public Mainnet Beta, developers can now deploy smart contracts without approval, and users can freely engage with the Movement ecosystem. This marks the beginning of a new chapter for Move-based technology, combining robust security and better performance with Ethereum’s network affects” added Rushi Manche, Co-Founder, Movement Labs.

The launch features the canonical Movement bridge powered by LayerZero, enabling users to seamlessly transfer MOVE (the network’s native gas token), USDT, USDC, wBTC, wETH, and more to the Movement chain.

The Movement Network Foundation will continue to launch additional features over time as the ecosystem evolves.

For more information about Movement Public Mainnet Beta, For more information about Movement’s Developer Mainnet, visit movementnetwork.xyz or follow @movementlabsxyz, @movementfdn, @moveecosystem @Move_Collective on Twitter.

About Movement Network Foundation
Movement Network Foundation is the driving force behind the Movement ecosystem, dedicated to fostering innovation and advancing the adoption of MoveVM technology. The foundation oversees the development of Movement Network, a next-gen solution built using MoveVM that settles to Ethereum. Through its MoveDrop program and ecosystem initiatives, the foundation supports developers, projects, and community contributors building decentralized applications. Learn more at movementfdn.xyz or follow @movementfdn on X.

MEDIA CONTACT:
Carmen Pearson
Head of PR & Communications
Movement Labs
Carmen.Pearson@MovementLabs.xyz

 

70mai Unveils 4K Omni: The Ultimate 360° Dash Cam for Unmatched Protection

SHANGHAI, March 10, 2025 /PRNewswire/ — 70mai, a leading innovator in dash cam technology, introduces the 70mai 4K Omni, an advanced upgrade to the world’s first 360° rotating dash cam, delivering comprehensive protection in any driving scenario. Now equipped with dual-channel recording, it pairs a 4K Sony STARVIS 2 front camera with a 1080P HDR rear camera, ensuring seamless 360° coverage. With 4K 60FPS recording, every detail is captured with cinematic precision, even at high speeds.

70mai 4K Omni
70mai 4K Omni

Whether navigating city streets or parking in low-light conditions, the 4K Omni delivers superior imaging. MaiColor Vivid+ Solution™ enhances brightness and clarity, while windshield color compensation reduces glare for crystal-clear visuals. 70mai Night Owl Vision™ enhances nighttime visibility, while 70mai Lumi Vision ensures reliable footage even in near-total darkness.

For round-the-clock vehicle security, the 24-Hour Smart Parking Surveillance system provides:

  • Instant App Alerts for collision notifications
  • Live Streaming for real-time remote monitoring
  • Find My Car for effortless vehicle tracking
  • Live Route Tracking for up-to-the-minute positioning

Powered by AI Motion Detection 2.0 and dual Hall Effect Sensors, the 4K Omni precisely detects movement, while 4G connectivity (UP05 for North America, UP04 for Europe) enhances remote surveillance, ensuring peace of mind wherever you are.

Unlike conventional dash cams, the 4K Omni features a supercapacitor, ensuring high-temperature resistance and automatic video saving before power loss, making it ideal for extreme conditions. On the road, Super-Sensing ADAS provides lane departure warnings, forward collision alerts, and pedestrian detection, actively enhancing driver safety.

Designed for effortless connectivity, the 4K Omni integrates Wi-Fi 6 for high-speed transfers, 512GB expandable storage, and multi-language voice control. Combining innovation, intelligence, and reliability, the 70mai 4K Omni sets a new industry standard for dash cam technology.

TCI Biotech Announces Strong 2024 Financial Performance, Sets Sights on Global Growth in 2025

TAIPEI, March 10, 2025 /PRNewswire/ — TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year ending December 31, 2024. The company reported steady revenue performance, strong profitability, and continued investment in innovation to drive future growth.

Executive Commentary

“Our 2024 financial performance underscores TCI Biotech’s resilience and ability to navigate market fluctuations while maintaining strong profitability,” said Vincent Lin, CEO of TCI Biotech. “We remain committed to expanding smart manufacturing, fostering strategic partnerships, and driving cutting-edge research. By strengthening our financial position, we aim to deliver sustainable growth and long-term value for our stakeholders.”

Financial Highlights

  • Revenue: NT$7.24 billion in 2024
  • Gross Profit: NT$3.18 billion, representing a gross margin of 44%
  • Operating Profit: NT$1.03 billion, maintaining a stable 14% operating margin
  • Net Profit: NT$974 million, with earnings per share (EPS) of NT$7.60
  • Dividend: NT$10 per share, reflecting solid financial performance
  • Cash and Cash Equivalents: NT$4.77 billion, ensuring strong liquidity

Key Business Developments

  • Expansion in International Markets: Sales growth in key regions, including North America, Europe, China and Asia, reinforcing TCI Biotech’s global footprint.
  • Innovation & R&D: Advances in liquid supplements and skincare, aligned with market trends. The newly established TCI Medical Consultation Panel enhances research and ensures scientific rigor.
  • Operational Efficiency: Strategic cost management and AI-enhanced production processes have contributed to maintaining profitability despite industry challenges.
  • Sustainable Growth Strategies: Continued commitment to ESG (Environmental, Social and Governance) initiatives to enhance corporate responsibility and long-term value creation.

Outlook for 2025

TCI Biotech is optimistic about its growth trajectory for 2025, focusing on balanced regional expansion, optimized production capacity, and strategic partnerships with global enterprises. With a commitment to quality, innovation, and customer-centric solutions, the company anticipates sustained momentum in revenue and profitability, reinforcing its position as a leader in biotechnology and smart manufacturing.

For more information, please visit www.tci-bio.com.

About TCI Biotech

TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence, TCI delivers high-quality, clinically backed products that empower customers worldwide.

Disclaimer: This press release contains forward-looking statements based on current expectations and assumptions, which involve risks and uncertainties. Actual results may differ due to market conditions, regulatory changes, or other unforeseen factors. TCI Biotech assumes no obligation to update forward-looking statements. Investors are advised to review the full financial report and consult professional advisors before making any investment decisions.

/C O R R E C T I O N — Newmark Group, Inc./

In the news release, Newmark Report: Resilient Singapore Office Demand Backed by Steady Economic Growth, issued 06-Mar-2025 by Newmark Group, Inc. over PR Newswire, we are advised by the company that the first sentence of the release should read “Newmark has released a study on the Singapore office leasing market.” rather than “Newmark has released a study, led by its Valuation & Advisory and Leasing & Brokerage teams, on the Singapore office leasing market.” as originally issued inadvertently. The complete, corrected release follows:

Newmark Report: Resilient Singapore Office Demand Backed by Steady Economic Growth

SINGAPORE, March 7, 2025 /PRNewswire/ — Newmark has released a study on the Singapore office leasing market. The report considers broader economic factors and ongoing trends among occupiers, projecting a positive year ahead for office leasing activity and continued moderate rental growth amid limited supply and stable economic growth on the island in 2025. 

Newmark Group, Inc.
Newmark Group, Inc.

“Increasing office-using employment and declining office supply should help to better balance the market’s supply and demand over the next 12 months, supported by steady economic growth and export growth,” said Chris Carver, MRICS, MSISV, AAPI, Executive Managing Director and Head of Asia-Pacific Valuation & Advisory. “With a limited development pipeline and sustained need for high-quality office space, we anticipate that rental growth will remain positive in 2025 and occupiers will continue to focus on workplace efficiency and employee experience, driving interest for prime spaces.”

Among the key 2024 takeaways:

  • Office vacancy rose slightly to 9.4% in 2024, largely attributable to the addition of the 1.25-million-square-foot IOI Central Boulevard Towers to the office supplyi.
  • Singapore’s CBD Grade A office rents grew approximately 2% in 2024 and are projected to increase at a moderate pace of around 2% in 2025. This growth is attributed to the limited supply of new office space in the CBD and sustained demand for premium office spacesii.
  • Flight to Quality remains a key driver of office relocations, as businesses prioritize talent acquisition and retention.
  • Service sectors, such as information and communications, financial and professional services, all grew in 2024 and are projected for further growth in 2025, which should in turn drive additional office demandiii.

Read the full report here and visit https://www.nmrk.com/insights to explore more Newmark Thought Leadership.

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2024, Newmark generated revenues of over $2.7 billion. As of December 31, 2024, Newmark and our business partners together operated from approximately 170 offices with more than 8,000 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

i Source: URA (Private Sector only) & Newmark Research
ii Source: URA & Newmark Research
iii Source: Ministry of Manpower (MOM)

ISLE 2025 Concludes with Great Numbers and New Trends: AI Empowering Smart Displays and System Integration, Ushering in a New Industry Ecosystem

SHENZHEN, China, March 10, 2025 /PRNewswire/ — ISLE 2025, Asia’s largest exhibition for smart display and system integration, was successfully held at the Shenzhen World Exhibition and Convention Center (Shenzhen World) from March 7 to 9, 2025.

ISLE 2025 attracted over 220,000 visits from global professional buyers from 100+ countries. More than 1,000 online and onsite exhibitors showcased latest products and solutions in display and integrated system, spanning an exhibition area of 80,000 square meters.

AI Reshaping the Boundaries of the Display Industry

As one of the most transformative technologies of our time, AI is redefining application scenarios within the display industry. In the fields of smart conferencing, home theaters, commercial displays, educational and medical display solutions, hundreds of companies presented AI-powered products equipped with intelligent operating systems in ISLE 2025. These cutting-edge solutions align with emerging technological trends, optimizing smart display functionalities and enhancing user experiences.

Cross-Industry Synergy between Displays and AV Systems

At ISLE 2025, the fusion of visual presentation, sound and interaction was taken to new height. Exhibitors presented cutting-edge integrated system solutions through large-scale live shows and demonstrations. The 1000 square meter “YUE Glamour Gloshine” immersive visual show, was a thrilling and enriching experience for visitors. Seamless fusion and collaboration from dozens of branded exhibitors, like NovaStar’s LED display control system and ARTSOUND’s stage audio equipment, achieved precise synchronization between visuals and audio, and delivered a captivating, immersive sensory experience for audience.

Global Innovation with Differentiated Focus

Shenzhen, as China’s hub for innovation and cutting-edge manufacturing, provided buyers unique advantages in finding tech-savvy suppliers. ISLE exhibitors were adopting differentiated strategies — leveraging high-brightness displays, energy-efficient designs, and intelligent interactive solutions — to expand their footprint in the international market.

ISLE Organizing Committee apprised 100 Excellent Products Awards among the tens of thousands of exhibits onsite, honoring those exhibitors pushed the boundaries of great performance, efficient maintenance, and eco friendliness.

The next session of ISLE will be held from March 6-8, 2026 in Shenzhen World Exhibition and Convention Center.

For updates, please follow ISLE at:
ISLE Facebook: https://www.facebook.com/isleshenzhen
ISLE LinkedIn: https://www.linkedin.com/in/international-smart-display-and-integrated-system-exhibition-shenzhen-3a6a6a10a/ 
ISLE YouTube: https://www.youtube.com/@ISLEOfficialAcc
ISLE Twitter: https://x.com/ISLEOfficialAcc
Official website: https://www.isle.org.cn/?lang=en&locale=en 

Phoenix Aviation Capital, AIP Capital and LuminArx Announce Acquisition of Three Airbus A330-300 Aircraft

Acquired aircraft are currently on lease to China Airlines and EVA Air

DUBLIN and STAMFORD, Conn. and NEW YORK, March 10, 2025 /PRNewswire/ — Phoenix Aviation Capital (“Phoenix“), a full-service aircraft lessor, AIP Capital, an alternative investment manager focused on opportunities in asset-based finance and LuminArx Capital Management (“LuminArx”), a global capital solutions provider, have jointly acquired a portfolio of three Airbus A330-300 aircraft.

The portfolio includes two 2012 vintage Airbus A330-300 aircraft (MSN 1346 and 1367), both powered by GE CF6 engines and leased to China Airlines. The third aircraft, a 2015 vintage Airbus A330-300 (MSN 1690), is also powered by GE CF6 engines and leased to EVA Air.

“We are pleased to have executed this transaction with LuminArx,” said Mathew Adamo, Managing Partner at AIP Capital and board member of Phoenix. “LuminArx was an exceptional partner – creative, solutions-oriented, and highly efficient in execution. Their ability to understand our position, then structure and close made this acquisition seamless. We look forward to building upon this successful partnership in the future.”

“We are delighted to have partnered with AIP Capital to complete the financing for the purchase of these three aircraft,” said Sanjeev Mordani, Partner at LuminArx. “AIP’s ability to navigate complex aviation transactions and find long-term value made them an invaluable partner in this acquisition. We found their hands-on approach and deep understanding of the aviation finance market instrumental. We look forward to expanding our collaboration and exploring new opportunities across adjacent asset classes.”

Vinson & Elkins LLP served as transaction counsel and KPMG acted as tax advisor to AIP Capital. Milbank LLP served as transaction counsel and PwC acted as tax advisor to LuminArx.

About Phoenix Aviation Capital

Phoenix Aviation Capital is a full-service aircraft lessor focused on financing modern, in-demand aircraft and is dedicated to meeting the financing needs of its airline customers across the globe. Phoenix Aviation Capital is based in Dublin and is managed by AIP Capital, a global aviation asset management and investment firm.

For more information about Phoenix Aviation Capital or to speak with company executives, please contact investor.relations@phoenixaviationcap.com.

About AIP Capital

AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance. AIP believes its unique investment strategy, relationships, and hands-on approach enable AIP to execute its mission of generating attractive risk-adjusted returns for its clients across market cycles. With offices in Stamford, New York City, Dublin, and Singapore, AIP maintains a global footprint and is backed by a full platform of professionals across finance, technical, legal, risk management and underwriting.

For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com

About LuminArx Capital Management

LuminArx Capital Management is a global alternative investment manager focused on providing innovative, flexible, and strategic capital solutions. The Firm targets consistent returns across market environments, prioritizing downside protection, retaining upside participation, and maintaining minimal correlation with traditional markets. LuminArx leverages a diverse ecosystem of relationships across banks, corporations, governments, and insurance companies, and partners with leading institutional investors across the globe.

Learn more at www.luminarx.com.

Media Contacts

AIP Capital
Geoffrey Bayers
investor.relations@aipcapital.com

LuminArx Capital Management
Dan Zacchei / Kate Sylvester
luminarx@longacresquare.com

LuminArx Logo

 

Sunway Medical Centre named top Malaysian Hospital in Newsweek’s World’s Best Hospitals ranking

SUBANG JAYA, Malaysia, March 10, 2025 /PRNewswire/ — Sunway Medical Centre, Sunway City (SMC) has yet again ranked in the top 250 hospitals globally in the latest Newsweek’s World’s Best Hospitals 2025 rankings.

(from left) Dato Lau Beng Long, President, Sunway Healthcare Group (SHG); Dr Khoo Chow Huat, Managing Director, Hospital & Healthcare Operations, SHG; Dr Seow Vei Ken, Chief Executive Officer, Sunway Medical Centre, Sunway City (SMC); Dr Low Kwai Siong, Medical Director, SMC; and Tan Mei Shin, Senior Director, Business Development and Corporate Communications, SMC
(from left) Dato Lau Beng Long, President, Sunway Healthcare Group (SHG); Dr Khoo Chow Huat, Managing Director, Hospital & Healthcare Operations, SHG; Dr Seow Vei Ken, Chief Executive Officer, Sunway Medical Centre, Sunway City (SMC); Dr Low Kwai Siong, Medical Director, SMC; and Tan Mei Shin, Senior Director, Business Development and Corporate Communications, SMC

Honoured for the second consecutive year, SMC improved from rank 233rd in 2024 to rank 193rd in 2025, and also is the top hospital in Malaysia in the latest listing.

The rankings list top 250 hospitals globally from 30 countries based on a comprehensive survey that gathered insights from medical experts, patient surveys, hospital quality metrics, and Statista Patient-Reported Outcome Measures (PROMs) Implementation Survey.

Dato’ Lau Beng Long, President of Sunway Healthcare Group remarked, “As the flagship hospital of Sunway Healthcare Group, SMC takes pride in its commitment to excellence in healthcare and hospitality in driving us to this level of international recognition. Being ranked among the top 250 hospitals globally, with the likes of the Mayo Clinic, The John Hopkins Hospital, Singapore General Hospital, and The University of Tokyo Hospital for two consecutive years is a testament to the unwavering dedication of our team especially medical specialists, nurses and allied health professionals.”

“We are proud to lead the way in Malaysia, and this achievement reaffirms our aim to provide the highest level of clinical care and to continue elevating the overall healthcare status in the country.”

The latest accomplishment builds upon SMC’s recent success in Newsweek’s Asia’s Top Private Hospitals 2025 ranking, where it was ranked 2nd in Asia for cataract surgery, and 3rd in Asia for refractive eye surgery, while also featured in the top 10 of Asia’s ranking for hip surgery and hip replacement (6th); knee surgery and knee replacement (6th); and shoulder surgery (10th).

The hospital was also featured in Newsweek’s Best Specialist Hospitals Asia Pacific list for 2023 and 2024.

Dato’ Lau also made history as the first Malaysian healthcare leader to be inducted in Newsweek’s Top Hospital CEOs 2024 list, alongside other prominent CEOs from the globe’s leading medical facilities.

As Malaysia’s largest private quaternary hospital, SMC is the first hospital in Malaysia to achieve three major hospital-wide accreditations: Joint Commission International (JCI) Accreditation, The Gold Seal of Approval from the United States; the Australian Council on Healthcare Standards (ACHS); and the Malaysian Society for Quality in Health (MSQH).